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cardiac function and incidence of 
unexplained myocardial scarring 
in patients with primary carnitine 
deficiency - a cardiac magnetic 
resonance study
Kasper Kyhl  1,2, Tóra Róin1, Allan Lund3, Niels Vejlstrup2,4, Per Lav Madsen5,6, 
thomas engstrøm4,6 & Jan Rasmussen1,4
Primary carnitine deficiency (PCD) not treated with L-Carnitine can lead to sudden cardiac death. To 
our knowledge, it is unknown if asymptomatic patients treated with L-Carnitine suffer from myocardial 
scarring and thus be at greater risk of potentially serious arrhythmia. Cardiac evaluation of function 
and myocardial scarring is non-invasively best supported by cardiac magnetic resonance imaging 
(CMR) with late gadolinium enhancement (LGE). The study included 36 PCD patients, 17 carriers and 17 
healthy subjects. A CMR cine stack in the short-axis plane were acquired to evaluate left ventricle (LV) 
systolic and diastolic function and a similar LGE stack to evaluate myocardial scarring and replacement 
fibrosis. LV volumes and ejection fraction were not different between PCD patients, carriers and 
healthy subjects. However, LV mass was higher in PCD patients with the severe homozygous mutation, 
c.95 A > G (p = 0.037; n = 17). Among homozygous PCD patients there were two cases of unexplained 
myocardial scarring and this is in contrast to no myocardial scarring in any of the other study 
participants (p = 0.10). LV mass was increased in PCD patients. L-carnitine supplementation is essential 
in order to prevent potentially lethal cardiac arrhythmia and serious adverse cardiac remodeling.
Primary carnitine deficiency (PCD) not treated with L-Carnitine can lead to sudden cardiac death1,2. Patients 
homozygous for the PCD related c.95 A > G mutation in SLC22A5 have been shown to be especially vulnerable 
with regards to potentially lethal cardiac arrhythmia. This genotype is especially prevalent in the small island 
community of the Faroe Islands3,4. Cardiac fibrosis assessed by late gadolinium enhancement (LGE) with cardiac 
magnetic resonance (CMR) is positively correlated to ventricular tachyarrythmias and SCD in various cardi-
omyopathies5–7. Late gadolinium enhancement (LGE) with cardiac magnetic resonance (CMR) is a marker of 
myocardial fibrosis of any etiology8.
PCD is an autosomal recessive disorder of fatty acid oxidation caused by a dysfunctional organic carnitine 
(OCTN2) transporter. The transporter is highly expressed in myocardial cells and consequently attains a high 
plasma-myocardial gradient of carnitine. A dysfunctional OCTN2 transporter reduces this gradient because of 
a compromised myocardial carnitine transport as well as a result of low plasma carnitine concentration subse-
quent to excessive renal loss of carnitine. However, carnitine is a vital metabolite for the heart as it is necessary for 
the transfer of long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. Apart from 
an increased risk of SCD other major findings in PCD include cardiomyopathy in especially children as well as 
hepatic failure and the most common symptom fatigue. Patients are treated with daily oral L-carnitine supple-
mentation to prevent development of complications4.
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Although PCD can cause lethal cardiac arrhythmia current treatment strategy does not include the use of 
an implantable cardioverter defibrillator (ICD) as primary prophylaxis. It is unknown if asymptomatic patients 
treated with L-Carnitine could still be susceptible to cardiac arrhythmia because of undiagnosed myocardial 
damage and fibrosis due to carnitine deficiency.
The aim of this study was to evaluate and compare cardiac function and myocardial scarring as late gado-
linium enhancement with CMR in PCD patients with carriers and healthy subjects in order to assess if current 
prophylactic treatment strategy should be reevaluated.
Methods
Sixty-eight subjects (18–75 years; 48 men) were included in the present study. Thirty-six patients with two dif-
ferent PCD genotypes were included: 17 patients homozygous for the c.95 A > G mutation and 17 patients com-
pound heterozygous for c.95 A > G and a risk-haplotype (RH) in SLC22A5. Seventeen carriers of a PCD related 
mutation in SLC22A5 and 17 healthy subjects were also included (Table 1).
The number of identified adult PCD patients homozygous for the c.95 A > G mutation alive in the Faroese 
population was 26 – of whom two had migrated, two had an implantable cardiac defibrillator (ICD) and therefore 
excluded, two patients declined to participate due to personal issues at the time and three patients suffered from 
claustrophobia.
All PCD patients received daily oral L-carnitine supplementation and were monitored in an outpatient setting 
with regular blood carnitine measurements. Carriers of a PCD related mutation are not treated with L-carnitine.
Ethics, consent and permissions. All participants were informed orally and in writing and gave informed 
written consent before participation. The Faroese Ethics Committee and the Data Protection Agency approved 
the study and the study was carried out in accordance with the Helsinki Declaration.
Consent to publish. Written consent to report individual patient data was obtained from participants if 
applicable.
Mutations and genotypes. Patients were included from a nationwide screening program in the Faroe 
Islands. Individuals with blood levels of free carnitine below a lower cut-off level of 5 micromol/L were geneti-
cally tested for mutations related to PCD3. In a previous study, patients homozygous for the missense mutation 
c.95 A > G mutation in SLC22A5 were shown to have only a mean residual OCTN2 transporter activity of 4% of 
normal, while patients compound heterozygous for the c.95 A > G mutation and the risk-haplotype (RH) have 
an 18% mean residual OCTN2 transporter activity9. The PCD carriers included in the study were carriers of the 
c.95 A > G mutation and were in the previous study shown to have a mean residual OCTN2 transporter activity 
of 46% compared to individuals without PCD9.
CMR acquisition and analysis. All patients underwent a CMR scan to evaluate left ventricular (LV) vol-
umes, mass, systolic and diastolic function and scar tissue. CMR was performed on a 1.5 T scanner (Siemens, 
Aera, Erlangen, Germany) with a dedicated cardiac coil. LV volumes and mass were assessed using a steady-state 
free precession cine sequence (slice thickness 8 mm, no gap, echo time 1.5 ms, field of view 300–360 mm, phases 
25). Multiple slices in both the short-axis and axial imaging planes were obtained covering the entire cardiac 
fossa. LV volumes were determined in the entire cardiac cycle (25 phases corresponding to a temporal reso-
lution of 25–45 ms) using semi-automated endocardial contour detection with papillary muscles included in 
myocardial mass. Based on identification of LV myocardium, the part of the basal slice belonging to the LV was 
included, and the LV outflow tract was included based on reference to the 3-chamber image10. Stroke volume 
(SV) was end-diastolic volume (EDV) minus end-systolic volume (ESV). LV ejection fraction (LVEF) was SV 
divided by EDV (%). All volumes are presented as indexed to body surface area (BSA). Scar tissue was assessed 
using a delayed enhancement inversion-recovery sequence (slice thickness 8 mm, echo time 1.4 ms, field of view 
300–360 mm, no slice gap; Fig. 1). Images were obtained 10 minutes after administration of diethylenetriamine 
pentaacetic acid (0.15 mL/kg; Gadovist, Bayer Schering, Berlin, Germany). Myocardial scarring was defined 
as enhanced myocardium in the LGE short-axis image sequences (>5 standard deviations above the intensity 
of normal myocardium; Fig. 1). LGE images was evaluated visually by two board certified CMR analyzers and 
c.95 A > G 
carriers n = 17
c.95 A > G/RH 
n = 17
c.95 A > G/c.95 A > G 
n = 17 p-value
Mean age (years) 35 (13) 38 (13) 32 (14) 0.44
Mean age at CTD diagnosis 29 (13) 33 (13) 26 (15) 0.20
Gender
    Men 12 (71%) 13 (77%) 12 (71%) 0.91
    Women 5 (29%) 4 (24%) 5 (29%)
BMI (kg m−2) 28 (5) 26 (5) 28 (5) 0.44
plasma L-carnitin, mmol/L 20.6 (7.8) 19.0 (8.2) 18.3 (9.6) 0.73
Table 1. Baseline characteristics. Data are presented as n (%) or mean ± standard deviation. c.95 A > G 
carriers, heterozygote; c.95 A > G/RH, compound heterozygotes for c.95 A > G and the risk haplotype; 
c.95 A > G/c.95 A > G, homozygote. P-values are from an ANOVA analyses or the χ² test as relevant. A 
p-value < 0.05 are considered significant.
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disagreements were settled by consensus (PLM and NV). All other analyses were performed by one observer, 
blinded to all clinical data. All image processing was performed with dedicated software (CVI42 v. 4.0.1, Circle 
Cardiovascular Imaging, Calgary, Canada).
CMR with steady-state, free-precession sequences is considered the gold standard of cardiac chamber vol-
umes (17). CMR is the method of choice for quantification of scar tissue compared with single-photon emission 
computed tomography owing to superior reproducibility and spatial resolution (18–20). Intra- and inter-observer 
variability of LVEDV, LVESV, left atrial maximum volume has been tested by our group in another study. Intra- 
and interobserver variability was lower than 2.86% for all measures11.
Statistics. All continuous variables are reported as mean ± standard deviation (SD) and indexed to BSA 
(Mosteller´s formula) where appropriate. Binomial variables were expressed as numbers (%) and calculated dif-
ferences between proportions with the χ² test. Normal distribution was tested visually on a histogram of the 
residuals and differences between group means or medians were assessed using ANOVA and post-hoc analyses 
using Tukey’s post-hoc test. Correlation was evaluated with Spearman’s correlation coefficient. All CMR values 
were compared to published published 95% confidence interval12. P value (double-sided) <0.05 was considered 
significant. All statistical analyses were performed using R (version 3.0.3; R Development Core Team 2014, http://
www.R-project.org/) and GraphPad Prism 6.0c (GraphPad software inc., La Jolla, California, USA).
Results
There were no differences between the groups of subjects with regards to age, sex, body mass index (BMI) and 
plasma L-carnitine (Table 1). Mean age at diagnosis of c.95 A > G homozygous PCD was 26 (15) years with no dif-
ference between the groups (p = 0.20). We included 71% (N = 17) of the identified adult c.95 A > G homozygous 
PCD patients in the Faroese population (N = 26).
Two c.95 A > G homozygous PCD patients had unexplained myocardial LGE (Fig. 1). One patient had LGE in 
the midmyocardium in the basal inferolateral segments, and the other patient had LGE in the midmyocardium 
in the lateral midventricular segment. A third elderly c.95 A > G homozygous patient had subendocardial LGE 
(50% transmurality) in the anterior segments, however the pattern was consistent with his history of previous 
myocardial infarction, and hence was not included in the analysis. There were no findings of myocardial LGE in 
any of the other patients, carriers nor healthy controls (p = 0.10).
LVEDV, LVESV were not significantly different between groups, but LV myocardial mass (p = 0.037) was 
higher in c.95 A > G homozygous PCD patients (Table 2). Only one carrier subject and one c.95 A > G homozy-
gous PCD patient had LV myocardial mass above the published 95% confidence interval (Table 3). All other 
parameters were comparable to published normal values for the left heart (Table 3). There were no significant 
correlations between P-carnitine and LVEDV/BSA, LVESV/BSA, LVEF or LV mass (Fig. 2).
Discussion
Our main finding was that PCD patients homozygous for the severe c.95 A > G mutation had significantly higher 
LV mass and LV wall thickness compared to the other groups – with two of them exhibiting signs of unexplained 
myocardial scarring (12.5%) (Table 1). We found no difference in the overall cardiac function among the groups 
studied. To our knowledge, we are the first to systematically investigate a population of PCD patients for myocar-
dial scarring and function using CMR.
The incidence of PCD in The Faroe Islands is the highest recorded in the world (1:297)9 and to our knowledge, 
we are the first to systematically investigate a population of PCD patients for myocardiac scarring and function 
using CMR. PCD patients can present with symptoms of severe hypoketotic hypoglycaemia, hepatic dysfunction, 
cardiac arrhythmias, cardiomyopathies or SCD13–19. However, a majority of the patients reach adulthood without 
any other symptoms than decreased stamina and fatigue20,21. The challenge is though that untreated – and per-
haps treated - patients can be asymptomatic while still have an increased risk of SCD.
Figure 1. Cardiac magnetic resonance (CMR) examples of cardiac fibrosis involvement in primary carnitine 
deficiency (PCD). Arrows shows late gadelineum involvement representing cardiac fibrosis.
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We have previously shown, that the hearts of newly diagnosed adult PCD patients were within normal echo-
cardiographic ranges with no signs of structural abnormalities or cardiac hypertrophy – the results were though 
not stratified with regards to genotype22. CMR is superior to echocardiography to evaluate cardiac mass and 
dimensions, which could explain our novel finding of significantly higher mean LV mass in patients homozy-
gous for the c.95 A > G mutation compared to the other groups. It also underpins our assumption that the men-
tioned genotype is associated with the most pronounced liability to develop symptoms in the Faroese PCD patient 
cohort.
We found unexplained myocardial scarring using LGE in two PCD patients homozygous for the c.95 A > G 
mutation. A previously published case report from the US also described areas of LGE in a patient with PCD who 
had been non-compliant with regards to L-carnitine supplementation23. To our knowledge, the incidence of areas 
of LGE in a hitherto healthy PCD population has not been investigated. Hence, we included a healthy control 
population in this study of whom none had any areas of LGE (n = 17). Neither had any of the carriers (n = 17) or 
patients suffering from the less severe genotype c.95 A > G/RH (n = 17). Our finding of two patients with unex-
pected myocardial scarring is noteworthy and gives rise to important questions.
The presence of LGE in patients with various cardiovascular diseases has been shown to predict adverse out-
comes including ventricular tachycardia and ventricular fibrillation (VT/VF)6,7. A recent study in patients fulfill-
ing the criteria for an implantable cardiac defibrillator (ICD) due to heart failure with reduced ejection fraction 
showed that patients with no areas of myocardial LGE on CMR were in a lower risk of VT/VF24. Myocardial 
c.95 A > G 
carriers n = 17
c.95 A > G/RH 
n = 17
c.95 A > G/c.95 A > G 
n = 17 p-value
Heart rate (min-1) 70 (12) 71 (15) 64 (11) 0.21
LVEDV (mL m−2) 82 (15) 79 (16) 87 (14) 0.30
LVESV (mL m−2) 32 (8) 30 (7) 32 (6) 0.82
LVSV (mL m−2) 51 (9) 49 (11) 55 (11) 0.16
LVCI (L min-1 m−2) 3.5 (0.5) 3.4 (0.9) 3.5 (0.7) 0.96
LVEF (%) 62 (5) 61 (5) 63 (5) 0.52
LV mass (g m−2) 63 (11) 60 (13) 71 (14) 0.037
LV Peak Ejection Rate (ml s−1): 567 (100) 529 (152) 581 (139) 0.50
LV Peak Filling Rate (ml s−1): 537 (108) 501 (150) 616 (146) 0.05
LV Average wall thickening (%) 71 (13) 77 (16) 76 (17) 0.47
LV Average wall motion (mm) 8 (1) 8 (1) 9 (2) 0.09
Presence of fibrosis, n 0 (0%) 0 (0%) 2 (12%) 0.12
Table 2. Data from Cardiovascular magnetic resonance imaging. Data are presented as n (%) or 
mean ± standard deviation. LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVESV, left 
ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVEF, left ventricular ejection fraction; 
c.95 A > G carriers, heterozygote; c.95 A > G/RH, compound heterozygotes for c.95 A > G and the risk 
haplotype; c.95 A > G/c.95 A > G, homozygote. P-values are from an ANOVA analyses or the χ² test as relevant. 
A p-value < 0.05 are considered significant.
c.95 A > G carriers 
n = 17
c.95 A > G/RH 
n = 17
c.95 A > G/c.95 A > G 
n = 17
LVEDV/[mean]
n > 95% CI
1.05 (0.19)
2 (12%)
1.01 (0.21)
3 (18%)
1.12 (0.18)
5 (29%)
LVESV/[mean]
n > 95% CI
1.22 (0.31)
5 (29%)
1.17 (0.28)
2 (12%)
1.22 (0.22)
3 (18%)
LVSV/[mean]
n > 95% CI
0.97 (0.17)
1 (6%)
0.94 (0.21)
1 (6%)
1.06 (0.21)
3 (18%)
LVCI/[mean]
n > 95% CI
1.06 (0.17)
2 (12%)
1.04 (0.26)
1 (6%)
1.05 (0.22)
4 (24%)
LVEF/[mean]
n < 95% CI
0.92 (0.07)
4 (24%)
0.92 (0.08)
3 (18%)
0.94 (0.07)
3 (18%)
LV mass/[mean]
n > 95% CI
0.91 (0.17)
1 (6%)
0.87 (0.19)
0
1.03 (0.20)
1 (6%)
LV Peak Filling Rate/[mean]
n > 95% CI
1.07 (0.22)
0
1.00 (0.30)
0
1.23 (0.29)
0
Table 3. Comparisons to normal values for left heart parameters12,31. Data are presented as n (%) or 
mean ± standard deviation. Comparisons include ratios to published means and 95% percentiles and numbers 
(%) above respective percentiles. CI, confidence intervals; [mean], published mean value; LV, left ventricle; 
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVSV, left ventricular 
stroke volume; LVEF, left ventricular ejection fraction; c.95 A > G carriers, heterozygote; c.95 A > G/RH, 
compound heterozygotes for c.95 A > G and the risk haplotype; c.95 A > G/c.95 A > G, homozygote. *P < 0.05.  
A p-value < 0.05 are considered significant.
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scarring is thought to either induce or maintain ventricular arrhythmias in several ways: 1) scarring creates insu-
lating barriers that form alterations in conduction in the fibrotic tissue, resulting in re-entrant wave fronts of 
excitation; 2) scarring can be considered as the origin or modulator of cardiac after-potentials that lead to trig-
gered activity causing VT/VF; 3) oxidative and metabolic stress stimulate early after-depolarization; 4) in areas 
of myocardiac scarring the myocardium is less electrically connected and is hence more likely to initiate VT/VF 
(source-to-sink mismatches)25–29.
The relationship between myocardial scarring and VT/VF raises the question – are PCD patients with signs of 
myocardial scarring in an increased risk of SCD even when they adhere to their recommended L-carnitine sup-
plementation? Should these patients receive a primary prophylactic ICD to prevent SCD? The questions are very 
relevant in this group of patients, because the primary prophylactic treatment strategy was e.g. used in the before 
mentioned case from the US, where the patient was fitted with an ICD. However, it needs to be stated that the US 
patient case was non-compliant to medical therapy. Three Faroese patients have also previously received ICDs.
Even though two of the 17 patients homozygous for the c.95 A > G mutation did have signs of myocardial 
scarring, our study indicates that it is not a very common finding, even in patients suffering from severe forms 
of PCD. Our experience gained during the last decade seems to indicate that the best way to prevent cardiac 
arrhythmia is treatment with L-carnitine supplementation as there have been no incidences of cardiac arrhythmia 
in Faroese PCD patients treated with L-carnitine. Adherence to the treatment has also proven to be very good in 
most Faroese patients, which has been verified by regular measurements of blood carnitine in all patients. PCD 
patients treated with L-carnitine in the Faroe Islands are thus not offered primary prevention with an ICD, instead 
they are, apart from being treated with L-carnitine, also closely monitored in an outpatient setting with regular 
blood tests and consultations with a clinical geneticist and cardiologist.
Limitations. Although LGE is useful for reproducible assessment of myocardial scarring and replacement 
fibrosis, it is limited in its accuracy in the assessment of diffuse fibrosis. First of all, with conventional LGE imag-
ing sequences, signal intensity is expressed on an arbitrary scale that is different in every image, and no direct 
comparisons can be made; second, the late enhancement is defined through contrast from a healthy area to an 
area with increased extracellular volume area and hence scarring or diffuse fibrosis cannot be assessed30. In a 
number of disease states, diffuse fibrosis can be assessed by quantitative CMR relaxometry, incorporating T1 map-
ping with high reproducibility, however it was not possible in the present study to include T1 mapping sequences.
conclusions
Some PCD patients have unexplained myocardial scarring shown by LGE. A relation between myocardial scar-
ring, metabolic and oxidative stress and SCD has been shown in the literature. Hence, it can be speculated, that 
the myocardial scarring in some PCD patients combined with an oxidative or metabolic stress can be the sub-
strate of the increased risk of SCD in untreated patients with PCD. L-carnitine supplementation is essential in 
order to prevent potentially lethal cardiac arrhythmia.
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Figure 2. Plots showing the relation between (A) left ventricular end diastolic volume (LVEDV) and plasma 
carnitine levels (p-carnitine), (B) left ventricular end systolic volume (LVESV) and plasma carnitine levels 
(p-carnitine) and (C) left ventricular ejection fraction (LVEF) and plasma carnitine levels (p-carnitine). (D) 
left ventricular mass (LV mass) and plasma carnitine levels (p-carnitine). c.95 A > G carriers, heterozygote; 
c.95 A > G/RH, haplozygote; c.95 A > G/c.95 A > G, homozygote.
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Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on rea-
sonable request.
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